Multi Time Point Plotting on NeuroQuant Reports

Are you taking advantage of the multi-time point plotting (longitudinal tracking) when evaluating your patients? This feature provides physicians with additional information for ongoing patient evaluation and is especially helpful in continuing care for patients with chronic neurodegeneration.

Multi-time point plotting is available for all reported structures on the NeuroQuant report when one or more previous series exist on the system with the same patient ID. For greatest reproducibility, we strongly recommend using the same scanner and protocol.

The results of current measurement (colored in black) and the prior measurements (colored in gray) are displayed on a single report allowing the physician to quickly and easily evaluate any trend in the patient’s brain volume. See examples below.

When the patient data is already in the system:
The creation of multi-time point reports occurs automatically with no user interaction for all compatible data on the system for the same patient ID.

When the patient data is no longer in the system:
To create multi-time point plots for patients with previously processed NeuroQuant output that is no longer on your system; send or upload a previous NeuroQuant report (DICOM format suffix .dcm) to NeuroQuant prior to processing the follow-up scan.

The multi-time point feature is available on the Age Related Atrophy, Hippocampal Asymmetry, Multi Structure Atrophy, Brain Development and LesionQuant reports.

Cortechs.ai | Multi Time Point Plotting on NeuroQuant Reports

Age- and Sex-matched charts

More Resources

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.
Scroll to Top